Chronic IBD (Inflamatory Bowel Disease)-Ulcerative Colitis and Crohns Disease — Up to $100.00/visit
This study will investigate the safety and efficacy of Mirikizumab in inducing…
You may be able to take part in the study if you:
-are 18-80 years of age
- have an established diagnose of ulcerative colitis for 3 months or more
- have had an inadequate response to, loss of response to, or are intolerant to biologic therapy (defined as infliximab, adalimumab, golimumab, vedolizumab) for Ulcerative Colitis
- have had an inadequate response to, loss of response to, or are intolerant to conventional medications (defined as corticosteroids/prednisone, azathioprine [AZA], 6-Mecaptopurine [6-MP]) for the treatment of Ulcerative Colitis
-have not been helped by previous or current treatments
The study will last for about 32 weeks (approximately 7.4 months).
-are 18-80 years of age
- have an established diagnose of ulcerative colitis for 3 months or more
- have had an inadequate response to, loss of response to, or are intolerant to biologic therapy (defined as infliximab, adalimumab, golimumab, vedolizumab) for Ulcerative Colitis
- have had an inadequate response to, loss of response to, or are intolerant to conventional medications (defined as corticosteroids/prednisone, azathioprine [AZA], 6-Mecaptopurine [6-MP]) for the treatment of Ulcerative Colitis
-have not been helped by previous or current treatments
The study will last for about 32 weeks (approximately 7.4 months).
Compensation
During required fasting visits, you may submit an invoice for meal reimbursement up to $25.00.
If your home address is further than 45miles from the treatment center, you may be eligible for mileage reimbursement at the rate of $0.24/mile up to 250 miles. If your home address is further than 45miles from the nearest study treatment center, you and the person that accompanies you may be eligible, during endoscopy visits, for lodging and meals. If you qualify all of the above information will be discussed prior to consent with additional details for reimbursement qualifications.